Irene Becklund, serving as Principal Accounting Officer for Hims & Hers Health, Inc. (NASDAQ:HIMS), executed a series of stock sales totaling $370,518 in mid-June 2026. The transactions, documented in a recent SEC Form 4 filing, spanned June 16 and June 17 of that year. These dispositions were carried out under the framework of a Rule 10b5-1 trading plan, which Becklund originally adopted on November 5, 2025.
On June 16, 2026, Becklund sold 7,573 shares at a price of $30.25 per share. The following day, June 17, an additional 4,490 shares were sold at $31.50 per share. The sales prices for these transactions ranged between $30.25 and $31.50 per share. These sales came as HIMS stock trades at $31.89, with the company carrying a market capitalization of $7.42 billion. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value. The platform notes that stock price movements are quite volatile, with a beta of 2.4. For investors seeking deeper insights, InvestingPro offers 13 additional ProTips and comprehensive Pro Research Reports covering HIMS and 1,400+ other US equities.
These sales followed the vesting of Restricted Stock Units (RSUs) on June 15, 2026. On that date, Becklund acquired 15,971 shares of Class A Common Stock through the settlement of various RSUs. These RSUs represent a contingent right to receive one share of Class A Common Stock for each unit and vested over a four-year period on quarterly dates.
Also on June 15, 2026, 5,870 shares were disposed of by the issuer to cover tax withholding obligations in connection with the reported vesting and settlement of RSUs. These shares were valued at $30.17 each, totaling $177,097. Following these reported transactions, Irene Becklund directly holds 6,790 shares of Hims & Hers Health, Inc. Class A Common Stock.
In other recent news, Barclays raised its price target for Hims & Hers Health to $39 from $29, maintaining an Overweight rating. This decision follows proprietary data indicating a positive impact from the company's partnership with Novo Nordisk, which led to increased website traffic. Additionally, Leerink reiterated a Market Perform rating with a $25 price target as the company prepares for a regulatory meeting on compounded peptides. This meeting could influence the inclusion of peptides on the FDA's 503A Bulk List, potentially expanding Hims & Hers' offerings.
In corporate governance, Hims & Hers Health held its annual stockholders' meeting, where all nine director nominees were elected to serve until 2027. The company also appointed Dr. Anant Vinjamoori as Chief Medical Officer, who will oversee clinical guidance across several health categories. Furthermore, Canaccord Genuity reiterated a Buy rating with a $32 price target, highlighting the company's strategic shift toward preventive health and peptide treatments. These developments reflect ongoing changes and strategic moves within Hims & Hers Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you invest $2,000 in HIMS right now? ProPicks AI evaluates HIMS alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if HIMS is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space? Flash Sale - Price Goes Up Soon